Atyr Pharma Inc (ATYR)

$1.63

+0.14

(+9.4%)

Market is closed - opens 7 PM, 25 Jun 2024

Performance

  • $1.52
    $1.69
    $1.63
    downward going graph

    6.75%

    Downside

    Day's Volatility :10.06%

    Upside

    3.55%

    downward going graph
  • $1.08
    $2.24
    $1.63
    downward going graph

    33.74%

    Downside

    52 Weeks Volatility :51.79%

    Upside

    27.23%

    downward going graph

Returns

PeriodAtyr Pharma IncIndex (Russel 2000)
3 Months
-10.44%
0.0%
6 Months
-10.44%
0.0%
1 Year
-10.44%
0.0%
3 Years
-10.44%
-24.2%

Highlights

Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
0.0%
Return On Equity TTM
0.0%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
0.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0

Analyst Recommendation

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Atyr Pharma Inc
Atyr Pharma Inc
-10.44%
-10.44%
-10.44%
-10.44%
-10.44%
Moderna, Inc.
Moderna, Inc.
-10.57%
40.76%
13.78%
-37.71%
894.92%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
9.32%
25.23%
35.63%
93.24%
240.01%
Novo Nordisk A/s
Novo Nordisk A/s
6.12%
38.57%
80.99%
243.67%
456.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
6.28%
16.51%
36.7%
144.39%
163.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Atyr Pharma Inc
Atyr Pharma Inc
NA
NA
NA
0.0
0.0
0.0
NA
NA
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.05
31.05
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.39
49.39
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.4
30.4
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Atyr Pharma Inc
Atyr Pharma Inc
NA
$102.8M
-10.44%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.1B
894.92%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.0B
240.01%
31.05
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.3B
456.0%
49.39
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.0B
163.64%
30.4
39.46%

Company Information

atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation

Organization
Atyr Pharma Inc
Employees
56
CEO
Sanjay Shukla
Industry
Miscellaneous

FAQs